Stocks and Finance

InterMune

InterMune 4/10/2012

10:48 : Brean Murray is cutting its price target to $37 from $42 on InterMune ... - Brean Murray is cutting its price target to $37 from $42 on InterMune (ITMN -1%) to reflect a more conservative outlook than the guidance management provided. The firm cites the potential denial of European coverage for Esbriet and a ...
Source : seekingalpha-com

InterMune 4/9/2012

11:55 : InterMune tumbles on study update - BOSTON (MarketWatch) -- Shares of InterMune Inc. tumbled 13% to $13.24 on Monday in the wake of news that a key clinical trial for its respiratory drug Esbriet has been delayed. Last Thursday, InterMune said it does not ...
Source : marketwatch-com

InterMune 3/15/2012

11:51 : InterMune climbs on German regulatory update - BOSTON (MarketWatch) -- Shares of InterMune Inc. climbed 8% to $15.94 on Thursday on news that German regulators have issued a positive assessment of its new drug Esbriet, a move that should ensure continued reimbursement for the product ...
Source : marketwatch-com

InterMune 1/9/2012

14:18 : Shares of InterMune ([[ITMN]] +10.4%) go on an INHX-inspired tear. The ... - Shares of InterMune (ITMN +10.4%) go on an INHX-inspired tear. The firm offers a protease inhibitor used by Roche's Hepatitis C treatment candidate. Post your comment!
Source : seekingalpha-com

InterMune 12/16/2011

18:05 : InterMune to 'vigorously' fight German report on lung drug - InterMune Inc.’s drug to treat a deadly lung condition provides little benefit to patients, according to a German health organization. The findings, published Thursday, could be a blow for Brisbane-based InterMune (NASDAQ: ...
Source : bizjournals-com
12:40 : InterMune slides for second day - BOSTON (MarketWatch) -- Shares of InterMune Inc. sank for the second day, down 9% at $11.54 in midday trading Friday. On Thursday, InterMune shares tumbled over 20% on news that German regulatory advisers had determined ...
Source : marketwatch-com

InterMune 12/15/2011

12:39 : InterMune plunges 21% in midday action - BOSTON (MarketWatch) -- Shares of InterMune Inc. were down 21% in midday action, last trading at $14.43 amid unusually high volume. The biotech company is currently in the midst of launching its lead product, Esbriet, in Germany. ...
Source : marketwatch-com

InterMune 9/14/2011

09:29 : InterMune prices offerings, seeks $222M - InterMune Inc. will sell 4 million shares at $24 each and offer $135 million in convertible senior notes at 2.5 percent, the company said in a Securities and Exchange Commission filing late Tuesday. The offerings, expected to close around ...
Source : bizjournals-com

InterMune 9/13/2011

21:32 : InterMune prices stock, note offerings, seeks $222 million - InterMune Inc. will sell 4 million shares at $24 each and offer $135 million in convertible senior notes at 2.5 percent, the company said in a Securities and Exchange Commission filing late Tuesday. The offerings, expected to close around ...
Source : bizjournals-com
10:50 : InterMune tumbles 9% on stock offering - BOSTON (MarketWatch) -- Shares of InterMune Inc. tumbled 9% to $24.40 on Tuesday, the day after the biotech group announced it plans to sell 4 million shares of its common stock and $100 million in convertible senior notes due in 2018. ...
Source : marketwatch-com

InterMune 9/12/2011

18:47 : InterMune (ITMN) announces a concurrent secondary offering of up to 4M ... - InterMune (ITMN) announces a concurrent secondary offering of up to 4M shares of common stock - boosting its total outstanding to around 6.6% - along with $100M of convertible senior notes. Shares -6.6% AH. Post your comment!
Source : seekingalpha-com
actualidad InterMune -


Biotechnology

Pharmaceuticals

Medical Supplies

Medical Equipment

Health Care Providers

Copyright © 2009 Finaperf.com - Exchange rate - Investir - Stock Exchange - Börse - Finanças - Bolsa - Tous droits réservés
Site édité par Yanga.net - Contacts